| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 109.1 | 109.2 | 97.6 |
| Other income | 3.8 | 2.8 | 1.7 |
| Total income | 112.9 | 112.0 | 99.3 |
| Profit before exceptional items & tax | 28.3 | 29.0 | 25.3 |
| Profit before tax | 28.3 | 29.0 | 25.3 |
| Net profit | 21.0 | 21.1 | 18.9 |
| Operating margin | 25.1% | 25.9% | 25.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +11.10% |
|---|---|
| Net profit, quarter on quarter | -0.50% |
| Revenue, year on year | +11.80% |
NSE results filing, NSE: VIMTALABS. Figures extracted from the filing.
Vimta Labs Ltd: key numbers
- Share price
- ₹599.30
- Market cap
- ₹2,679 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 33.6×Sector 57.8×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120 Mn and PAT of ₹211 Mn with strong margins across TIC segments.